tert-Butyl 4-benzyl-2-(hydroxymethyl)piperazine-1-carboxylate

Catalog No.: 
ACZKTX951
CAS No.: 
936553-15-0
Molecular Formula: 
C17H26N2O3
Molecular Weight: 
306.41
tert-Butyl 4-benzyl-2-(hydroxymethyl)piperazine-1-carboxylate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
100mg97%$172.00InquiryInquiry
250mg97%$312.00InquiryInquiry
1g97%$779.00InquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Nametert-Butyl 4-benzyl-2-(hydroxymethyl)piperazine-1-carboxylate
IUPAC Nametert-butyl 4-benzyl-2-(hydroxymethyl)piperazine-1-carboxylate
Molecular FormulaC17H26N2O3
Molecular Weight306.41
SMILESO=C(N1C(CO)CN(CC2=CC=CC=C2)CC1)OC(C)(C)C
InChI KeyYFBKIGOBELWXJV-UHFFFAOYSA-N
Synonymtert-Butyl4-benzyl-2-(hydroxymethyl)piperazine-1-carboxylate;1-Piperazinecarboxylic acid, 2-(hydroxymethyl)-4-(phenylmethyl)-, 1,1-dimethylethyl ester;1-Boc-4-benzyl-2-(hydroxymethyl)piperazine
CAS No.936553-15-0

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P280-P301+P312-P302+P352-P305+P351+P338

Synthetic Route by SureRoute

1. ACZKTX951 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACZKTX951 route product structure diagram
    ACZKTX951936553-15-0
Inquiry

2. ACZKTX951 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACZKTX951 route product structure diagram
    ACZKTX951936553-15-0
Inquiry

3. ACZKTX951 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACZKTX951 route product structure diagram
    ACZKTX951936553-15-0
Inquiry

Comments (0)